Search

Displaying results 1761 - 1770 of 10000 in total
  1. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]

    Products: CLIVARIN 5726 IE A XA/ML, CLIVARODI 17178 A XA/ML
  2. Target

    tRNA-dihydrouridine(20a/20b) synthase [NAD(P)+]-like

    go.drugbank.com/bio_entities/BE0022092
    EnzymeHumans

    Catalyzes the synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs

    Polypeptides: tRNA-dihydrouridine(20a/20b) synthase [NAD(P)+]-like
  3. Pathway

    2-Ketoglutarate Dehydrogenase Complex Deficiency

    smpdb.ca/view/SMP0000549
    Disease

    oxoglutarate dehydrogenase complex (OGDC). … 2-Ketoglutarate dehydrogenase complex deficiency, also known as alpha-ketoglutarate dehydrogenase deficiency or oxoglutaric aciduria, is an autosomal recessive disorder of the Krebs cycle caused by a defective

    Drugs: Pyruvic acid · Biotin · Succinic acid · NADH · ATP · Magnesium cation +4 more
    Enzymes: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial
  4. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

    Products: Amicar Inj 250mg/ml, Amicar Syr 250mg/ml
  5. Drug

    Meldonium

    go.drugbank.com/drugs/DB13723
    Investigational

    Products: SATURID 100 MG/ ML I.V. ENJEKSIYONLUK ÇÖZELTI IÇEREN AMPUL
  6. Drug

    Cerebrolysin

    go.drugbank.com/drugs/DB16599
    Investigational

    Products: Ambotonin 215,2 mg/ml - parenterale Lösung Injektionslösung/Konzentrat zur Herstellung einer Infusionslösung
  7. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    FDA approved on May 28, 2009.

    Products: BESIVANCE % 0,6 OFTALMIK SÜSPANSIYON, 5 ML
  8. Pathway

    Pyruvate Dehydrogenase Complex Deficiency

    smpdb.ca/view/SMP0000212
    Disease

    PDHA1 encodes the pyruvate dehydrogenase complex (PDC) a critical complex that converts pyruvate from glycolysis to acetyl CoA for the citric acid cycle. … Pyruvate dehydrogenase complex deficiency results from a mutation in the E1-alpha polypeptide gene (PDHA1).

    Drugs: Pyruvic acid · Biotin · Adenosine phosphate · Glutathione · NADH · ATP +13 more
    Enzymes: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial
  9. Pathway

    Mitochondrial Complex II Deficiency

    smpdb.ca/view/SMP0000548
    Disease

    Interestingly, complex II deficiency gene mutation carriers may be at an increased risk for certain cancers. … Because complex II is found in the mitochondria, CII deficiency is technically considered a mitochondrial disease.

    Drugs: Pyruvic acid · Biotin · Succinic acid · NADH · ATP · Magnesium cation +4 more
    Enzymes: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial
  10. Pathway

    Copper gluconate Drug Metabolism

    smpdb.ca/view/SMP0130548
    Metabolic

    Copper gluconate passes through the liver and is then excreted from the body mainly through the kidney. … Copper gluconate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis.

    Drugs: Copper gluconate